title: A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia.
abstract: Twenty-five patients (22 adults and 3 infants) with ALL1/AF4-positive acute lymphoblastic leukemia (ALL) were prospectively monitored by reverse transcriptase-polymerase chain reaction (RT-PCR) between January 1992 and July 1999. After high-dose induction and consolidation chemotherapy without bone marrow transplantation, all patients had a complete hematologic remission. Using nested RT-PCR (sensitivity 10(-4)), we observed conversion to PCR negativity in 11 (44%) of the patients. Thirteen of the 14 patients who did not have a molecular remission had a relapse at a median time of 4 months (range, 1 - 20 months). Of the 11 patients who had a conversion to PCR negativity, 5 reconverted to PCR positivity within 1 to 14 months. These 5 patients all progressed to hematologic relapse after 2, 3, 4, 4, and 7 months, respectively. Of the remaining 6 patients, 4 are in persistent hematologic and molecular remission at 12, 14, 88, and 96 months, whereas 2 are early in their follow-up. Actuarial probabilities of relapse and overall survival were 100% and 0% at 14 and 24 months and 67% and 43% at 96 and 100 months, respectively, in patients who had persistent RT-PCR positivity and in those who had a molecular remission. For both relapse and survival, the differences observed between the two groups were significant (P =.003 and P <.005, respectively). This study, which represents the first prospective analysis of residual-disease monitoring carried out in a substantial series of patients with t(4;11)-positive ALL, emphasizes the clinical relevance of RT-PCR-based methods to monitor minimal residual disease in this leukemia subset. (Blood. 2000;95:96-101)
authors.affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy. cimino@bce.med.uniroma1.it
authors.forename: G
authors.initials: G
authors.lastname: Cimino
authors.forename: L
authors.initials: L
authors.lastname: Elia
authors.forename: M C
authors.initials: MC
authors.lastname: Rapanotti
authors.forename: T
authors.initials: T
authors.lastname: Sprovieri
authors.forename: M
authors.initials: M
authors.lastname: Mancini
authors.forename: A
authors.initials: A
authors.lastname: Cuneo
authors.forename: C
authors.initials: C
authors.lastname: Mecucci
authors.forename: G
authors.initials: G
authors.lastname: Fioritoni
authors.forename: M
authors.initials: M
authors.lastname: Carotenuto
authors.forename: E
authors.initials: E
authors.lastname: Morra
authors.forename: V
authors.initials: V
authors.lastname: Liso
authors.forename: L
authors.initials: L
authors.lastname: Annino
authors.forename: G
authors.initials: G
authors.lastname: Saglio
authors.forename: G
authors.initials: G
authors.lastname: De Rossi
authors.forename: R
authors.initials: R
authors.lastname: Foà
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000328:Adult; D002880:Chromosomes, Human, Pair 11; D002894:Chromosomes, Human, Pair 4; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014178:Translocation, Genetic
chemical_list: C403194:ALL1-AF4 fusion protein, human; D015514:Oncogene Proteins, Fusion